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Abstract
Objective: To quantify the impact of antiretroviral therapy (ART) on mortality in HIV-positive people during tuberculosis (TB)
treatment.
Design: We conducted a systematic literature review and meta-analysis. Studies published from 1996 through February 15,
2013, were identified by searching electronic resources (Pubmed and Embase) and conference books, manual searches of
references, and expert consultation. Pooled estimates for the outcome of interest were acquired using random effects meta-
analysis.
Subjects: The study population included individuals receiving ART before or during TB treatment.
Main Outcome Measures: Main outcome measures were: (i) TB-case fatality ratio (CFR), defined as the proportion of
individuals dying during TB treatment and, if mortality in HIV-positive people not on ART was also reported, (ii) the relative
risk of death during TB treatment by ART status.
Results: Twenty-one studies were included in the systematic review. Random effects pooled meta-analysis estimated the
CFR between 8% and 14% (pooled estimate 11%). Among HIV-positive TB cases, those receiving ART had a reduction in
mortality during TB treatment of between 44% and 71% (RR=0.42, 95%CI: 0.29–0.56).
Conclusion: Starting ART before or during TB therapy reduces the risk of death during TB treatment by around three-fifths
in clinical settings. National programmes should continue to expand coverage of ART for HIV positive in order to control the
dual epidemic.
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Introduction
Infection with HIV dramatically increases individuals’ risk of
developing active tuberculosis (TB) disease, as well as the risk of
death during TB treatment [1]. While 13% of all people with TB
are estimated to be HIV positive, they account for approximately a
quarter of TB deaths [2]. The African region, where 250,000
deaths occurred among HIV-positive TB cases in 2012, accounts
for 75% of HIV-positive TB cases [2].
Globally, in 2012, 46% of notified TB cases had a documented
HIV test result and the coverage of Antiretroviral therapy (ART)
among TB patients known to be HIV-positive was estimated to be
57% [2]. ART reduces the impact of HIV on incident TB, as
illustrated by Suthar et al. who showed that the risk of TB is
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e112017reduced by 65% [3]. Also, results from various trials and
observational studies have consistently shown a benefit of ART
on TB outcomes, and indicated that ART should be initiated as
early as possible in the course of a TB episode [4,5,6,7,8,9,10,11].
However, to date, there has been no systematic overview of the
magnitude of benefit of ART on TB mortality. A recent systemic
review by Straetemans et al. on TB mortality stratified subjects by
HIV status but did not explore the effect of ART [12].
TB mortality in HIV-positive people is a key parameter to
describe current state and progress in TB care and control [2].
Ideally, TB mortality is estimated through direct measurements
using vital registration systems or mortality surveys, but these are
often unavailable in resource limited settings, where TB incidence
is highest [2]. Alternatively, TB mortality can be estimated
indirectly by calculating the case fatality ratio (CFR), which is
defined as the proportion of people with incident TB that die as a
result of this episode of disease [13]. TB-CFR has been defined by
Maher et al. as the proportion of TB cases that die within a
specified time [14]. In particular, Mukadi et al. defined TB-CFR
as the proportion of tuberculosis patients that die during TB
treatment [15], which is the definition applied by Straetemans et
al. in their review [12].
In this paper we systematically review the literature to estimate
the mortality during TB treatment among HIV-positive TB
patients receiving ART as well as its value relative to HIV-positive
TB patients not receiving ART.
Methods
The review’s methods were defined in advance following the
Prepared Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines [16].
Criteria for considering studies
Study population. We included studies that described
mortality among HIV positive patients receiving TB treatment
who initiated combination ART before or during TB treatment.
All sex and age groups were included.
Our focus was on estimating the effect of ART as it applied to
TB patients from the general population, and we excluded cohorts
that were limited to recurrent, extra-pulmonary or known drug-
resistant TB patients only. We also excluded studies focusing on
populations of patients not representative of the general popula-
tion such as miners [17], prisoners [18], healthcare workers [19] or
injecting drug users [20].
Study design and sample size. Eligible study designs
included clinical trials, prospective cohort, retrospective cohort
and case-control studies. Literature reviews were screened to
retrieve relevant primary data. Studies which reported mortality
results on fewer than 50 TB patients receiving ART were also
excluded.
Outcome measures. We focused on deaths occurring
during TB treatment, the main operational parameter used in
the field by most TB control programmes. This outcome has the
benefit of a clearly defined at-risk period which facilitates between-
study comparisons as well as programmme monitoring and
evaluation. Papers were therefore excluded if they did not report
mortality within six to eight months after start of TB treatment or
otherwise restrict patient follow-up to the end of treatment.
We considered two primary outcome measures. Firstly, the TB-
CFR defined as percentage of deaths among the study population
occurring during TB treatment. Secondly, if the paper also
reported TB mortality in HIV-positive individuals not on ART,
we recorded the estimated relative risk (odds ratio (OR), relative
risk (RR) or hazard ratio (HR)) of death during TB treatment by
ART status.
Search methods for identification of studies
Studies were identified by searching the electronic databases
Medline and Embase. The strategy was first developed in Medline
and then adapted for use in the other databases (Appendix A).
Studies published in English from 1996 (when combination ART
first became available) through July2014 were included. In
addition, the abstract books of the world conferences on lung
health of the International Union against Tuberculosis and Lung
Diseases (IUATLD) were manually scanned for the period 2004–
2013 and further studies were retrieved from reference lists of
relevant articles and consultation with experts in the field.
Data collection and analysis
Data extraction. Identified studies were independently
reviewed for eligibility by two authors in a two-step process; a
first screen was performed based on title and abstract while full
texts were retrieved for the second screen. At both stages
disagreements between reviewers were resolved by discussion.
Data were extracted by one author supervised by a second
author using a standardised data extraction spreadsheet. The data
extraction spreadsheet was piloted on 10 randomly selected papers
and modified accordingly. Data extraction included: authors’
names, year and country of publication, study design, study
setting, study period, age of study participants, information on TB
type, TB diagnosis and drug resistance, information on time of
ART initiation, follow-up time, information on analysis performed
and outcomes of interest. We defined TB treatment to be
standardized (following the definition used by Straetemans [12])
if it was described to be: i) in line with WHO recommendations, ii)
following national or governmental guidelines, iii) direct observed
treatment strategy (DOTS) or iv) defined as ‘standard’ [12].
Analysis. We performed descriptive analysis to report the
characteristics of the included studies. Midpoint values for the age
of the included cohorts was based on the reported mean or median
and were pooled as weighted averages. With regard to the pre-
specified outcomes, we would expect variability between studies,
e.g. based on average CD4 count in the study population or
general quality of local health systems. We therefore applied
random effects analyses to acquire an estimate of the average effect
of ART on TB mortality, rather than assuming a single true value
in a fixed effects approach [21]. With regard to the pre-specified
outcomes, heterogeneity was assessed using the I
2 statistic and
visual inspection of forest plots [21]. Depending on data
availability, we planned to conduct sub-group analyses (where
relevant and possible) by WHO region, age-group, time interval
between TB treatment start and ART start, laboratory-confirmed
TB diagnosis and median CD4 count at start of study. If
unadjusted and adjusted outcomes were available, we recorded the
adjusted estimate to reduce the risk of confounding.
Quality assessment. The same two authors who performed
data extraction independently assessed the quality of the included
studies using the Newcastle-Ottawa Assessment Scale (NOS) [22].
Level of quality was not set as a criterion for exclusion.
Disagreements by reviewers were resolved by consensus.
Results
Identified studies
We identified 2,129 records by searching the selected databases
and listing references of relevant articles. After removing
duplicates, 1,825 articles were retrieved. Papers were screened
The Impact of Antiretroviral Therapy on Tuberculosis Mortality
PLOS ONE | www.plosone.org 2 November 2014 | Volume 9 | Issue 11 | e112017and selected as illustrated in Figure 1, resulting in 21 studies that
were included in the systematic review and meta-analysis.
Characteristics of included studies
The characteristics of the included studies are reported in
Table 1. The majority of the studies were conducted in the
African (n=11, 52%) [14,23,24,25,26,27,28,29,30,31,32] and
South-East Asian (n=7, 33%) [33,34,35,36,37,38,39] regions;
two studies were conducted in South America [40,41] and one in
Europe [42]. Four out of seven studies in the South-East Asian
region were conducted in Thailand [33,35,37,38] while one used
data from eighteen sites in the Asia-Pacific region [39]. Both South
American studies were conducted in Brazil.
More than half of included studies (n=13, 62%) described a
retrospective cohort [23,24,25,27,34,37,40,42], seven (33.3%)
described prospective cohort studies [14,26,33,35,38,41] and one
was a clinical trial [36]. We excluded seven papers
[5,6,7,8,9,43,44] reporting results from large trials that focused
on time of ART initiation during TB treatment as TB mortality
data was only reported at time points that lay beyond our pre-
specified ‘during treatment’ period [6,7,43,44], the outcome was
death combined with AIDS-defining illness and mortality data
could not be extrapolated [7] or focused only on tuberculous
meningitis [9]. Study enrollment periods ranged from 4 months
[30] to 8 years [40]. The majority of the studies were conducted
predominantly in urban settings (n=14, 66.7%)
[12,23,24,25,26,29,30,31,32,36,40,41,42]. Table 2 shows the lev-
els of quality assigned to each study. We determined that the
majority of the studies were susceptible to mild cohort selection
bias because of their retrospective study design
[23,24,25,27,34,37,40,42]. We did not assess ten eligible studies
for comparability as they were descriptive studies not reporting
effect estimates [14,23,25,27,28,31,36,37,39,42]. Among the rest,
we judged that five had moderate comparability, because
confounding factors were not fully adjusted or they were not
specified [24,29,30,34,35]. For most studies, the assessment of
outcomes was done by medical record review which we regarded
as susceptible to mild outcome bias (Table 2).
Characteristics of the study populations
86% (n=18) studies reported on source of data and method of
data collection; of these, data were mostly collected from medical
records (n=10, 56%) and TB registers (n=5, 28%). Three studies
explicitly reported on how death was ascertained or confirmed
(Table 2) [38,39,45].
For most studies (n=19, 90.5%) only a fraction of the total
patient population included TB cases that started ART before or
during TB treatment. For example, in Agodokpessi et al., of the
total patient population, 259/1086 (24%) were HIV positive and
of these 259, 85 (33%) initiated ART before or during TB
treatment [23]. On average, 50% of the studies’ study population
(range: 12–100%) fitted our criteria (Table 1). The number of
included patients per study ranged from 75 [33] to 21,851 [29],
with a median of 191 subjects. Studies included predominantly
young adults (age midpoint: 34. years, SD: 61.9).
All but two [14,25] studies reported on TB type: among them,
the percentage of individuals with pulmonary TB ranged between
19.4% and 100% (median: 66%). Where reported, most subjects
Figure 1. PRISMA flow diagram of papers selected.
doi:10.1371/journal.pone.0112017.g001
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Drug susceptibility profiles were reported by nine studies. Three
studies only included drug-sensitive TB cases and in the remaining
studies, the proportion with multi-drug resistance was low and
ranged from 0.1%–7% (median: 1.5%; included in the review).
Three studies reported that some TB patients did not receive
standardized therapy [35,38,42]. Details on TB treatment
regimens are available in Table S3. Descriptions of TB type, TB
category and drug susceptibility in the majority of studies referred
to the original studies’ entire cohorts and not to the subsets of the
study population selected for this analysis.
Eleven studies reported that a proportion of their patients
initiated ART before TB treatment (between 18 and 66%,
Table 1), but the actual ART start dates were not reported
[24,26,28,29,30,33,34,38,39,41,42]. Where all patients were
initiated on ART during TB treatment, the median start times
occurred in month 2 or 3 after starting TB treatment
[14,25,27,32,36,37]. The variability in reporting between studies
Table 2. Source of data, method of death ascertainment or confirmation and quality assessment of the included studies.
Reference
Source of data and method
of data collection
Method of death
ascertainment/confirmation The Newcastle-Ottawa Scale
Selection Comparability Outcome
Agodokpessi 2012 [23] Data were extracted from medical records Na *** **
Akksilp 2007 [33] Surveillance and monitoring data from
public health program
Na *** ** **
Dean 2002 [42] Data were extracted from medical records Na ** **
Dos Santos 2013 [40] Data were extracted from medical records
by trained health care workers
Na *** ** **
Ferroussier 2013 [28] Data were extracted from TB registers Na *** **
Gandhi 2012 [14] Na Na ** **
Henegar 2012 [24] Na (we assume Data were extracted from
medical records)
Na ** *
Kaplan 2013[29] Data were extracted from the national
electronic TB register
Na *** * **
Kayigamba 2013 [30] Data were extracted from TB registers
and TB treatment charts
Na ** **
Kendon 2012 [25] Data were extracted from medical records Na ** **
Nansera 2012 [26] Na Na ** ** *
Raizada 2009 [34] Data were extracted from medical records Na *** * **
Sanguanwongse 2008 [35] Data were extracted from medical records Na *** * **
Schmaltz 2009 [41] Data were extracted from medical records Na ** * **
Sileshi 2013 [31] Data were extracted from medical records
(Pre-ART registers, lab requests, follow-up
forms, anti TB record forms, ART intake
forms, and patient cards).
The patients’ date of death
was extracted from TB
registration log books
** *
Sinha 2012 [36] Clinical and laboratory data actively
collected and reported on an ad hoc
electronic data base.
Na -
a -
a -
a
Tansuphasawadikul 2007 [37] Data were extracted from medical records Na * **
Tweya 2013 [32] Data were extracted from TB registers and
TB treatment cards. Deaths were
ascertained mainly through active
follow-up.
Na *** ** **
Varma 2009 [38] Data were extracted from medical
records and the Thailand TB Active
Surveillance Network.
To determine if patients
died after defaulting
notification data were
linked to the Thai
government’s
vital status registry.
*** ** **
Zachariah 2007 [27] Data were extracted from TB registers
(counselling registers, district TB registers,
TB patient cards, ART Patient Master
Cards and ART Registers)
Na ** **
Zhao 2014 [39] TREAT Asia HIV Observational Database
(TAHOD)
Death was confirmed
by local medical staff and reported
using standardized Cause of Death
(CoDe) forms
** **
-aNewcastle-Ottawa Quality assessment scale not applicable (study design: randomized trial, higher level of evidence as compared to observational studies [60].
doi:10.1371/journal.pone.0112017.t002
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ART initiation times with respect to the start of TB treatment.
Data on CD4 count were very heterogeneous and incomplete
and did not allow quantitative assessment of effect modification
(Table S2). In six (29%) studies, data on CD4 count were not
reported at all [24,27,30,32,34,40]; in four (19%) studies they were
not available for the subgroup of the study population included in
the meta-analysis [14,33,38,41]; and in five (24%) studies the
percentage of the study population included in the meta-analysis
for which some measures of CD4 count were available did not
exceed 55% [23,26,28,37,42]. Median CD4 count was available
for .98% of subjects included in the meta-analysis in four (19%)
studies [31,35,36,39] and ranged from 48 to 152 cells/mm
3.
Follow-up time corresponded to TB treatment duration in 18
(75%) studies. In Sinha et al., follow-up time was set at six months
after TB treatment start or at TB treatment completion, and in
Kendon et al., it was set at six months from ART start (ART was
started within 56 days from TB treatment start) [36].
One study reported outcomes which were limited to bacterio-
logically-confirmed (positive sputum smear or culture result) TB
cases [27,35] and one study included only culture-confirmed TB
cases [35].
Outcome measures
Sixteen studies reported data on CFR (Table 3)
[14,23,25,27,28,30,31,33,34,35,36,37,38,39,41,42]. Meta-analysis
of the CFR showed high heterogeneity (I-squared =89.9%, p,
0.001, Figure 2). The random-effects analysis suggested the CFR
lay between 8% and 14% (point value =11%; Figure 2). The
pooled CFR appeared slightly higher in the African region (11%–
17%), and lower in the South-East Asian (7%–15%) region. The
CFR was 4% (95%CI: 0%–7%) and 13% (95%CI: 6%–21%) in
single studies set in the UK and Brazil respectively (Figure 2).
Sanguanwongse et al. considered a subgroup of patients with very
low CD4 counts at the start of TB treatment (CD4 ,10 cells/
mm3), which experienced a CFR of 21% (95%CI: 1%–32%) [35].
When restricted to the four studies where all patients were initiated
on ART after starting TB treatment, the CFR was 12% (95% CI
8%–17%).
Eleven out of 21 studies reported data on estimated relative risk
of mortality comparing people taking vs. not taking ART
Figure 2. Forest plot of 16 studies reporting TB-CFR for HIV positive patients receiving ART (by Region).
doi:10.1371/journal.pone.0112017.g002
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available for all but one study [26]. A random effects meta-analysis
showed that the relative risk of death during TB treatment by
ART status was 0.42 with a 95%CI: 0.29–0.56; (I-squared
=96.9%, p,0.001, Figure 3), which corresponds to a 44% to 71%
reduction in mortality. When we restricted the analysis to studies
considering only patients with smear positive TB (n=2) the
random effects relative risk was 0.11 (95%CI: 0.03–0.20) [35,38].
Discussion
We estimate that mortality during TB treatment in HIV-
positive individuals receiving ART under routine programmatic
conditions lies between 8% and 14% and that ART reduces the
mortality during TB treatment for HIV-positive TB cases by
between 44 to 71%.
This is the first systematic assessment to quantify the impact of
ART on TB mortality during TB treatment. In addition, we report
not only pooled absolute mortality figures as done elsewhere [12]
but also estimate the relative effect of ART on mortality, which has
the advantage of being a less setting-specific and a more easily
interpretable and generalizable parameter.
Our focus on deaths during TB treatment allowed us to make
optimal use of the limited data, while providing a clear conceptual
parameter that is widely used and reported by National TB
Programmes, and which allows comparison between studies and
other reviews. Mortality estimates over longer follow-up periods
have been reported in recent trials [6,7,8,43], but are not usually
reported in surveillance systems, operational research and clinical
settings. Previous reviews and reports have discussed the difficulties
in trying to determine which deaths are directly attributable to TB,
especially in low-resource settings [2,12]. Different studies
classified TB as either the primary or a contributory cause of
death [12,46]. In addition, according to the 10th revision of the
International classification of diseases (ICD-10), deaths in HIV-
positive TB patients are classified as HIV deaths [1]. In light of
these considerations, we systematically assessed the effect of ART
on death during TB treatment rather than deaths due to TB.
While the exclusion of several large RCTs reduced the number
of studies and patients included, it was necessary to ensure
between-study comparability regarding the time at risk of death.
When reported, we note that these RCTs found relatively
comparable TB-CFRs to our review [7]. We note that in the
CAMELIA trial, the CFR was substantially higher than our
estimate (18% and 27% for those initiating ART two or eight
weeks into TB treatment), but this is likely to be due to the very
low baseline CD4 count of patients included in that study (median
=25 cells/mm
3) and the longer follow-up time (median =25
months) [6]. As expected, other observational studies that
considered follow-up periods greater than 3.5 years also find
higher absolute mortality estimates [47].
Figure 3. Forest plot studies reporting the relative risk of death during TB treatment by ART status.
doi:10.1371/journal.pone.0112017.g003
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receiving ART is also below than the 19% point value reported by
Straetemans et al. amongst all HIV-positive TB cases, which
included some individuals receiving ART. This is consistent with
expected effect of ART to reduce TB mortality [12,27].
Sub-group analyses by geographical region suggested that the
CFR was higher in the African region (14%, estimates based on 7
studies) and lower in the one study from a Western European
setting (4%, in the UK), which mirror global TB mortality patterns
[2]. The reported differences in CFR between regions might also
be attributable to differences in immunosuppression at the time of
clinical presentation which could affect the estimated benefits of
ART. The protective effect of ART appeared stronger in people
with smear-positive TB, reflecting the better treatment outcomes
in this population across HIV/ART groups compared to patients
without smear or culture confirmation. This could be due to some
people who do not genuinely have TB being erroneously included
in the smear negative group. However, given the small number of
studies with bacteriological confirmation (n=2), this result should
be interpreted with caution.
A limitation of our work is that – due to a lack of data - we could
not explore the effect of ART by CD4 count. The lack of data is
due to the fact that the majority of the included studies reported
data from TB registers, and surveillance systems in high HIV-TB
burden and resource-limited settings where CD4 measurements
are often unavailable [48]. Recent data from large RCTs have
provided solid evidence that ART reduces mortality across a wide
range of CD4 counts [5,6,7]. In addition, the 2013 WHO
guidelines for antiretroviral therapy provide the evidence-based
recommendation that in subjects with active tuberculosis ART
should be initiated as soon as possible, irrespective of CD4 count
[49]. However, we found that on average patients were started two
to three months post TB treatment initiation, suggesting this may
not have been policy or practice in the majority of observational
studies included. If ART were provided to all HIV positive TB
patients as per current guidelines, we would expect the CFR to
decrease [8,43], and to see an even greater reduction in relative
mortality. The question of when to start ART in HIV-positive TB
patients has been addressed by the above-cited RCTs [5,6,7,8,50]
and - based on their findings - HIV and TB guidelines recommend
that among HIV-positive TB patients with CD4 less than 50 cells/
mm
3, ART should be initiated within 2 weeks from TB treatment
start and if CD4 above 50 cell/mm
3, within 8 weeks
[51,52,53,54,55]. Nonetheless, the issue remains controversial as
results from a recent trial reported no difference in mortality
between early and delayed ART for HIV-positive TB patients
with CD4 counts of 220 cells/mm
3 or more with authors arguing
WHO guidelines should be updated accordingly [44] while, on the
other hand, some researchers question the need of investing
resources in other randomized, controlled trials on the same topic
[56].
Nearly all data came from observational studies, which are
more vulnerable to bias. For example, sicker patients might be
more likely to be selected to start ART, thus introducing selection
bias that would under-estimate the effect of ART. However,
observational studies may better represent the patient population
and clinical care provided in most settings. The majority of the
studies considered single hospitals, local or district-level data and
this might limit the ability to generalize results to national or
regional level. Patients seen at referral hospitals may be sicker and
may experience higher mortality, while at the same time, those
treated in urban centres might have lower mortality than those
treated in rural settings. Last but not least, most studies relied on
TB notification registers and medical records whose degree of
completeness and quality of reporting might be different in
different settings, potentially introducing bias to pooled estimates.
Similar to other reviews, we did not consider mortality amongst
people lost to follow-up in our CFR estimates. Given that studies
have suggested mortality among patients lost to follow up and
transferred out averages 21% [57], our CFR is probably similarly
underestimated [12]. As we did not consider studies focusing on
special populations, our findings might not be generalizable to
subpopulations with additional risk factors for mortality.
We found a high degree of heterogeneity between studies, which
could be due to differences in clinical (e.g. CD4 count) or health
system variables. We did not apply meta-regression because of the
low number of studies, and the lack of information such as
duration on ART and CD4 at start of TB treatment. By reporting
results from random effects estimates, we acknowledge this
heterogeneity. Due to the low number of studies contributing to
the analysis, stratification by study quality was not possible. In
addition, 95% of studies included in our systematic assessment
have an observational study design which is subject to some risk of
bias. However, since our aim was to describe the risk of death
among HIV-infected TB patients under routine programmatic
conditions, observational studies likely provide the most relevant
data for this analysis.
In conclusion, we quantified the substantial impact of ART on
reducing mortality during TB treatment. Collaborative tubercu-
losis-HIV activities are key components of the new Post-2015
Global Tuberculosis Strategy, approved by the World Health
Assembly in May 2014 [58]. They include expanded collaboration
between TB and HIV programmes and integrated tuberculosis
and HIV service delivery in the field. For individuals newly
diagnosed with TB, this means increased on-site HIV testing, and
prompt referral for HIV care for all found to be HIV positive [59].
Improved harmonization relies on more sharing of clinical space
and integration of medical records, staff, and training. These
interventions promise to reduce delays to HIV diagnosis, facilitate
early implementation of effective ART and reduce TB-related
mortality in HIV positive patients.
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